您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > MK-5108(VX-689)
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
MK-5108(VX-689)
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
MK-5108(VX-689)图片
CAS NO:1010085-13-8
规格:98%
分子量:461.94
包装与价格:
包装价格(元)
5mg电议
10mg电议
50mg电议
200mg电议

产品介绍
Aurora-A kinase inhibitor,highly selective
CAS:1010085-13-8
分子式:C22H21ClFN3O3S
分子量:461.94
纯度:98%
存储:Store at -20°C

Background:

MK-5108, also known as VX-689, is a novel, potent and selective inhibitor of Aurora A kinase (AAK) that competitively binds to the ATP binding site of AAK and hence potently inhibits the activity of AAK with 50% inhibition concentration IC50value of 0.064 nM. MK-5108 also inhibits other members of Aurora kinase family, including Aurora B kinase (IC50= 14 nM) and Aurora C kinase (IC50= 12 nM), with a lesser potency. MK-5108 has been extensively studies and found to exhibit antitumor activity in a wide range of cancer types, including breast, cervix, colorectal, ovary and pancreas neoplasms.


Reference


?[1].Myke R. Green, BS, Pharm.D., BCOP, Joseph E. Woolery, BS, Pharm.D, and Daruka Mahadevan, MD, PhD. Update on Aurora Kinase Targeted Therapeutics in Oncology. Recent Pat Anticancer Drug Discov. 2008 November ; 3(3): 162–177.